search
Back to results

The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau

Primary Purpose

Malaria, Falciparum

Status
Unknown status
Phase
Phase 4
Locations
Guinea-Bissau
Study Type
Interventional
Intervention
acetaminophen (paracetamol)
Placebo
Sponsored by
Bandim Health Project
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malaria focused on measuring malaria, treatment, paracetamol, chloroquine, Guinea-Bissau, children, P.falciparum

Eligibility Criteria

undefined - 15 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: < 15 years of age Presenting at Bandim Health Centre Symptoms suggestive of malaria At least 20 P. falciparum parasites per 200 leukocytes Live in Bandim (to enable follow-up) Exclusion Criteria: Severely ill children considered to need the services of a hospital by the doctor in charge Previous idiosyncratic reactions to chloroquine or paracetamol

Sites / Locations

  • Bandim Health Project

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1 Paracetamol

2 Placebo

Arm Description

Paracetamol as per protocol

Inactive placebo as per protocol.

Outcomes

Primary Outcome Measures

parasite clearance time
recrudescence rate

Secondary Outcome Measures

well-being of the child

Full Information

First Posted
August 28, 2005
Last Updated
July 6, 2010
Sponsor
Bandim Health Project
search

1. Study Identification

Unique Protocol Identification Number
NCT00137566
Brief Title
The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau
Official Title
The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau
Study Type
Interventional

2. Study Status

Record Verification Date
July 2010
Overall Recruitment Status
Unknown status
Study Start Date
May 2004 (undefined)
Primary Completion Date
November 2006 (Actual)
Study Completion Date
January 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Bandim Health Project

4. Oversight

5. Study Description

Brief Summary
The National Malaria Programme in Guinea-Bissau recommends paracetamol for all children treated for malaria. We, the investigators of the Bandim Health Project, want to evaluate whether this treatment has any effect on: the well-being of the child; the parasite clearance time; and the rate of a re-appearance of parasites during 35 days of follow-up. Children presenting at Bandim Health Centre with malaria will be treated with chloroquine plus paracetamol or chloroquine plus placebo. Blood samples will be obtained daily for the first 4 days and then once a week until day 35.
Detailed Description
A Cochrane Review was unable to show a superior antipyretic effect of paracetamol compared with placebo in febrile children. Recent research suggests that the time to parasite clearance in non-severe malaria is longer in children being given paracetamol. As the costs associated with the use of paracetamol is not trivial and the risk of adverse effects is not negligible, we want to evaluate the effects of paracetamol on: the well-being of the child; the parasite clearance time; and the recrudescence rate. Children presenting at Bandim Health Centre with symptoms of malaria and a malaria film showing mono-infection with P.falciparum will, following consent to participate, randomly be allocated to treatment with chloroquine and paracetamol or with chloroquine and placebo. Blood samples will be obtained daily for the first 4 days. The children will be visited and a malaria film taken on day 7 and then weekly until day 35. On inclusion and whenever parasitaemia is detected a capillary blood sample will be taken for PCR analyses to be able to distinguish re-infection from recrudescence. During follow-up children are recommended to present at the health centre in case of persistent fever or any other symptoms. Examination and treatment will be free of charge. Whenever a child has re-infection sulfadoxine/pyrimethamine will be used for re-treatment following the recommendation of the National malaria Programme. After the inclusion of 80 children a preliminary analysis will be performed. If 50% or more of the children in any of the study arms have reappearing parasitaemia the study will be terminated. If the parasite clearance time and especially the recrudescence rate is higher for children being given paracetamol the current recommendation from the National Malaria Programme should be reconsidered. If children treated with paracetamol feel better during the acute illness making it more likely for them to have en adequate intake of food and liquid this benefit should be considered in the evaluation of the current recommendations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria, Falciparum
Keywords
malaria, treatment, paracetamol, chloroquine, Guinea-Bissau, children, P.falciparum

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized

8. Arms, Groups, and Interventions

Arm Title
1 Paracetamol
Arm Type
Experimental
Arm Description
Paracetamol as per protocol
Arm Title
2 Placebo
Arm Type
Placebo Comparator
Arm Description
Inactive placebo as per protocol.
Intervention Type
Drug
Intervention Name(s)
acetaminophen (paracetamol)
Intervention Description
Paracetamol tablets, 50 mg/kg/day for 3 days.
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
parasite clearance time
Time Frame
35 days
Title
recrudescence rate
Time Frame
35 days
Secondary Outcome Measure Information:
Title
well-being of the child
Time Frame
35 days

10. Eligibility

Sex
All
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: < 15 years of age Presenting at Bandim Health Centre Symptoms suggestive of malaria At least 20 P. falciparum parasites per 200 leukocytes Live in Bandim (to enable follow-up) Exclusion Criteria: Severely ill children considered to need the services of a hospital by the doctor in charge Previous idiosyncratic reactions to chloroquine or paracetamol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Aaby, Professor
Organizational Affiliation
Bandim Health Project
Official's Role
Study Director
Facility Information:
Facility Name
Bandim Health Project
City
Apartado 861
State/Province
Bissau
Country
Guinea-Bissau

12. IPD Sharing Statement

Citations:
PubMed Identifier
12856055
Citation
Russell FM, Shann F, Curtis N, Mulholland K. Evidence on the use of paracetamol in febrile children. Bull World Health Organ. 2003;81(5):367-72. Epub 2003 Jul 7.
Results Reference
background
PubMed Identifier
25421474
Citation
Jovel IT, Kofoed PE, Rombo L, Rodrigues A, Ursing J. Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012. Antimicrob Agents Chemother. 2015 Feb;59(2):872-9. doi: 10.1128/AAC.03554-14. Epub 2014 Nov 24.
Results Reference
derived
PubMed Identifier
21631932
Citation
Kofoed PE, Ursing J, Rodrigues A, Rombo L. Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: a randomized controlled trial. Malar J. 2011 Jun 1;10:148. doi: 10.1186/1475-2875-10-148.
Results Reference
derived

Learn more about this trial

The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau

We'll reach out to this number within 24 hrs